KCR’s Post

Merck Group & Kelun LifeSciences (Pvt)Ltd’s TROP-2 ADC could be a ray of hope post Phase III data readout highlighting its efficacy in the most aggressive breast cancer type, TNBC. Sacituzumab tirumotecan, known as SKB264, has demonstrated outstanding potential in the treatment of advanced triple-negative breast cancer (TNBC), substantially lowering the risk of disease progression or mortality while maintaining an acceptable safety profile. An interim analysis conducted on June 21, 2023, indicated that patients treated with SKB264 experienced a median progression-free survival (PFS) of 5.7 months, which is more than twice the 2.3 months observed in patients who received standard chemotherapy. The 6-month PFS rates further highlighted the difference, with SKB264 achieving a rate of 43.4% compared to 11.1% for chemotherapy. In patients exhibiting high TROP2 expression, the median PFS for SKB264 was 5.8 months, significantly longer than the 1.9 months for those on chemotherapy. DelveInsight Business Research LLP's American Society of Clinical Oncology (ASCO) 2024 Exclusive Coverage, Unlock the Best Expert Insights and Comprehensive Analysis @ https://lnkd.in/dmRMbVCf #ASCO24 #ASCO #ASCOconference #SacituzumabTirumotecan #SKB264 #AdvancedTNBCTreatment #CancerTherapyInnovation #ProgressionFreeSurvival #TROP2Expression #BreastCancerTreatment #OncologyBreakthroughs #ChemotherapyAlternatives #CancerSurvivalImprovements #TargetedCancerTherapy #TripleNegativeBreastCancer #CancerResponseRate #MedicalResearchAdvances  #HopeForCancerPatients #PersonalizedOncology #CancerTreatmentOptions

🚨 Big News in Oncology: Accelerating Market Access for Alpha DaRT® 🚨 Alpha Tau Medical Ltd. has been accepted into the FDA's prestigious Total Product Life Cycle (TPLC) Advisory Program! 🎯 This significant milestone will fast-track the commercialization of Alpha DaRT®, a groundbreaking cancer therapy, for patients with recurrent glioblastoma multiforme (GBM)—a devastating condition with limited treatment options. Why this matters: >GBM has a low five-year survival rate and affects over 14,000 patients annually in the U.S. 🧠 >Alpha DaRT® uses innovative alpha-emitters to destroy solid tumors, targeting the tumor while sparing healthy tissue. With this new FDA support, Alpha Tau aims to reduce time-to-market, patient access barriers, and streamline reimbursement pathways. 🩺💡 Looking forward to seeing how this will revolutionize cancer care for GBM patients! #HealthcareInnovation #FDA #Oncology #MedicalDevices #AlphaTau #Glioblastoma #CancerTherapy #AlphaDART #MarketAccess

I want to thank patients, investigators and their staff for participating in our clinical trial with monotherapy #roginolisib, which was presented by #AnnaMariaDiGiacomo at this year´s Annual Meeting of the American Society of Clinical Oncology (#ASCO2024) in Chicago (see https://lnkd.in/dFpfc_cX; also see: ASCO® 2024 Insights: "Roginolisib, an Oral, Highly Selective and Allosteric Modulator of PI3Kd for Uveal Melanoma and Advanced Cancers" | VuMedi).  We are excited to learn more about the activity of roginolisib in patients with metastatic uveal melanoma as we continue to analyze the biomarker data from patients treated with #roginolisib. Such data will be presented at future medical conferences.

During the plenary session at this year’s ASCO Annual Meeting, the NADINA phase 3 trial results were unveiled, marking a pivotal moment in melanoma treatment. Dr. Matthew Hadfield, Medical Oncologist at Brown University and Oncology Data Advisor Editorial Board member, delves into the groundbreaking significance of these results for patients with melanoma. Tune in to the video to explore: ⚪The shift towards neoadjuvant immunotherapy in melanoma ⚪The NADINA trial design and the combination of ipilimumab and nivolumab ⚪Event-free survival and major pathological response outcomes ⚪Toxicities and the importance of risk-benefit discussions ⚪The broader implications for oncology practice and future research 🔗 Watch the full video here: https://bit.ly/3zsvpFF #ASCO2024 #Melanoma #Immunotherapy #Oncology #MedicalResearch #ProfessionalDevelopment

The phase III ARANOTE trial evaluated the efficacy and safety of darolutamide in combination with androgen-deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC). The comprehensive results, presented today at #ESMO24 and simultaneously published in the Journal of Clinical Oncology, show a significant improvement in radiological progression-free survival (rPFS) with darolutamide plus ADT versus ADT alone. Darolutamide + ADT reduced the risk of disease progression or death by 46% compared to ADT alone. Median rPFS was not reached in the darolutamide group versus 25.0 months in the placebo group. Benefits were consistent across all subgroups, including high- and low-volume disease. Overall survival results were suggestive of benefit with darolutamide. The safety profile of darolutamide was favorable, with a lower incidence of fatigue compared to placebo. Read the full study here: https://brnw.ch/21wMHPd #ProstateCancer #pcsm #Oncology #ClinicalTrials #Darolutamide #ADT

🚨 New clinical trial started: GeparPiPPa (GBG 105) 🚨 We are pleased to present the recruiting #GeparPiPPa Phase II #study! This multicenter, randomized study is investigating #neoadjuvant #endocrine #therapy in combination with #trastuzumab and #pertuzumab +/- the PI3K inhibitor #inavolisib in patients with #HER2-positive, #HR-positive, #PIK3CA-mutated primary breast cancer. 🧬 The study is designed to evaluate the #efficacy and #safety of inavolisib in combination with dual anti-HER2 blockade. 170 #patients will be enrolled and evaluated for pathological complete response (#pCR). 💊 🔍 First patient enrolled in January 2023. 👉 Further information: https://lnkd.in/ewk4UaZw GBG Forschungs GmbH #CancerResearch #BreastCancer #ClinicalTrial #Oncology #EndocrineTherapy #GBG

Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC in China. Unprecedented: Ivonescimab Is the First Drug to Achieve Clinically Meaningful Benefit over Pembrolizumab in Randomized Phase III Clinical Trial in NSCLC. Monotherapy Ivonescimab Achieved Clinically Meaningful PFS Benefit in HARMONi-2 Trial Conducted by Akeso. PFS Improvement Was Observed Broadly in Patients Across Subgroups, including PD-L1 Low and PD-L1 High Expressing Tumors, Squamous and Non-Squamous Histologies. Full Data Set to be Presented at an Upcoming Major Medical Conference Planned for Later This Year. Conference Call to be Held at 8:00am ET on Monday, June 3, 2024. Full Press Release: https://lnkd.in/eD-bd27R #Ivonescimab #LungCancer #Akeso #Oncology #SummitTherapeutics

This is really useful and informative. 'Biomarker testing in NSCLC: patient and caregiver awareness and understanding.' COR2ED has shared the findings from the PRECISION ONCOLOGY CONNECT global survey on awareness and understanding of biomarker testing among patients with non-small cell lung cancer (NSCLC) and their caregivers. A group of international multidisciplinary clinical experts and patient advocacy group representatives designed the global survey which was presented in a poster at the ESMO - European Society for Medical Oncology Congress 2024. It can now be downloaded from the COR2ED website: https://lnkd.in/eTmERRAA #NSCLC #BiomarkerTesting #Biomarkers #PatientAdvocacy #survey #COR2ED #ESMO #ESMO24 #ESMO2024 #EuropeanSocietyforMedicalOncology #ESMOCongress #LungCancerEurope #LuCE #LCSM #lungcancer

"Transforming HER2+ Breast Cancer Treatment: A Journey of Innovation" Since 1998, the landscape of HER2+ Breast Cancer treatment has dramatically evolved, showcasing remarkable advancements in therapeutic options. From the initial approval of Trastuzumab + chemo, we've witnessed a cascade of FDA approvals enhancing patient outcomes and quality of life. Key Milestones: 1998: Trastuzumab + Chemo 2006: Lapatinib + Capecitabine 2013: T-DM1 2019: Trastuzumab Deruxtecan 2020: Margetuximab + Chemo, Tucatinib + Capecitabine + Trastuzumab These advancements underscore the relentless pursuit of innovation in oncology, offering hope and new horizons for patients worldwide. #ASCO24 #Oncology #BreastCancerAwareness #CancerTreatment #HealthcareInnovation #FDAApproval #HER2Positive #MedicalAdvancements #PatientCare Follow our page for more industry updates: https://lnkd.in/de5zNWmK

NEW from #ESMO2024 | NIAGARA: perioperative #durvalumab with neoadjuvant #chemotherapy in MIBC 🎥 🇪🇸 Guru Sonpavde, MD, Adventhealth Cancer Institute, gives an overview of the Phase III NIAGARA trial (NCT03732677), which assessed neoadjuvant #durvalumab plus #chemotherapy followed by radical #cystectomy and adjuvant #durvalumab in #cisplatin-eligible patients with muscle-invasive #bladdercancer (MIBC) 🔦 🌟 A statistically significant improvement in event-free survival and overall survival were reported, highlighting the practice-changing nature of the trial 🌟 Learn more 👉 https://lnkd.in/eqK-UQup #VJOncology #Oncologynews